Revenue and Income - Revenue for fiscal years 2025 and 2024 was $0, with past revenue derived from technology licensing and patent sales [172]. - Interest income decreased to approximately $673,000 in fiscal year 2025 compared to approximately $1,133,000 in fiscal year 2024 [177]. Expenses - Research and development expenses decreased by approximately $1,325,000 to approximately $5,071,000 in fiscal year 2025 from approximately $6,396,000 in fiscal year 2024 [175]. - Research and development expenses for cancer vaccines and CAR-T therapeutics in fiscal year 2025 were approximately $3,121,000 and $1,950,000, respectively [174]. - General and administrative expenses decreased by approximately $805,000 to approximately $6,630,000 in fiscal year 2025 from approximately $7,435,000 in fiscal year 2024 [176]. Cash Flow and Financial Position - Cash used in operating activities was approximately $7,173,000 during the fiscal year ended October 31, 2025 [181]. - Cash, cash equivalents, and short-term investments decreased approximately $4,750,000 to approximately $15,174,000 at October 31, 2025 [181]. - The company raised approximately $2,378,000 net of expenses through an at-the-market equity offering of 772,001 shares of common stock during the fiscal year [180]. - Expected future cash obligations related to office leases through 2029 are estimated at approximately $256,000 [182]. Net Loss and Market Risk - The net loss attributable to noncontrolling interest decreased by approximately $43,000 to approximately $101,000 in fiscal year 2025 [178]. - No quantitative and qualitative disclosures about market risk were required for the smaller reporting company [197].

Financial Position - As of December 31, 2025, Atara Biotherapeutics reported its cash, cash equivalents, and short-term investments, although specific figures were not disclosed in the preliminary estimate[6] Regulatory Challenges - The U.S. FDA issued a Complete Response Letter for the EBVALLO™ (tabelecleucel) Biologics License Application, indicating regulatory challenges for the product[7]

Sales Performance - Total Company net sales increased 15.6% to $464.7 million for the fourth quarter, with a comparable store sales increase of 5.4%[3] - U.S. net sales increased 20.6% to $364.5 million, with comparable store sales up 8.8%[3] - Canada net sales increased 9.1% to $100.2 million, with comparable store sales up 0.7%[3] - For fiscal 2025, total Company net sales reached $1.68 billion, a 9.2% increase, with comparable store sales up 4.7%[3] - The Company reported a constant-currency net sales increase of 8.4% for the fourth quarter, excluding the benefit of the 53rd week[3] - Total net sales for the fifty-three weeks ended January 3, 2026, reached $1,678,954,000, an increase of $126,113,000 or 8.2% over the prior year[19] - U.S. Retail sales for the same period were $940,185,000, reflecting a $90,052,000 increase or 10.8% compared to the previous year[19] - Canada Retail sales amounted to $608,093,000, with a year-over-year increase of $24,259,000 or 4.1%[19] - Other sales contributed $130,676,000, showing a $11,802,000 increase or 10.0% over the prior year[19] - The impact of foreign currency on total net sales for the fifty-three weeks was a decrease of $28,923,000[19] - The company reported a benefit of $13,699,000 from constant currency adjustments in total net sales for the fifty-three weeks[19] Financial Outlook - The Company reaffirms its fiscal 2025 Adjusted Net Income outlook of approximately $71 million to $75 million, or $0.44 to $0.46 per diluted share[2] - Adjusted EBITDA outlook for fiscal 2025 is approximately $252 million to $257 million[2] Shareholder Activities - During the fourth quarter, the Company repaid $20 million of principal under its term loan facility and repurchased approximately 1.1 million shares at an average price of $8.75[4] - The Company participated in the 28th Annual ICR Conference from January 12-14, 2026, to engage with investors[5] Retail Sales Data - For the thirteen weeks ended December 28, 2024, total net sales were $401,985,000, with no applicable year-over-year comparison[19] - U.S. Retail sales for the thirteen weeks were $220,463,000, with no applicable year-over-year comparison[19] - Canada Retail sales for the same period were $151,130,000, with no applicable year-over-year comparison[19] - Other sales for the thirteen weeks totaled $30,392,000, with no applicable year-over-year comparison[19] Currency Impact - The Company emphasizes the importance of constant-currency results for transparent period-to-period comparisons, excluding foreign currency fluctuations[12]

Revenue and Profit - Revenue for the 13 weeks ended September 27, 2025, was $7.575 million, an increase of approximately $2.6 million compared to $4.941 million for the same period in 2024[199]. - Gross profit for the same period increased to $2.623 million, up from $2.361 million, primarily due to the acquisition of Mswipe[200]. - Revenue for the 39 weeks ended September 27, 2025, was $19.5 million, a significant increase of approximately $12.4 million compared to $7.1 million for the same period in 2024[215][213]. - Gross profit for the 39 weeks ended September 27, 2025, was $8.0 million, representing a gross profit margin of 41.0%, compared to $3.5 million and a margin of 48.6% in 2024[216][214]. Expenses - Selling, general and administrative expenses rose significantly by approximately $17.6 million to $19.162 million, driven by higher bad debt expense and increased stock-based compensation[201]. - Selling, general and administrative expenses increased by approximately $22.1 million for the 39 weeks ended September 27, 2025, totaling $28.3 million, primarily due to increased bad debt and professional fees[217]. Net Income and Loss - The net loss from continuing operations before provision for income taxes was $58.734 million for the 13 weeks ended September 27, 2025[196]. - The net income (loss) for the 13 weeks ended September 27, 2025, was $48.962 million, compared to a loss of $(822) thousand for the same period in 2024[196]. - Net income from continuing operations for the 39 weeks ended September 27, 2025, was $38.8 million, compared to a loss of $1.1 million in 2024[212]. Adjusted EBITDA - Adjusted EBITDA for the 13 weeks ended September 27, 2025, was $(9.129) million, compared to $2.112 million for the same period in 2024, reflecting a consolidated adjusted EBITDA margin of (120.5%)[196]. - Adjusted EBITDA for the 39 weeks ended September 27, 2025, was $(10.8) million, a decrease of approximately $11.7 million compared to $0.9 million in 2024[227][226]. Cash Flow - Cash on hand as of September 27, 2025, was $7.3 million, with $3.5 million reserved for a legal matter[228]. - Cash used in continuing operations was approximately $15.5 million for the 39 weeks ended September 27, 2025, compared to cash provided by operations of approximately $3.7 million in 2024[230]. - Cash used in investing activities for continuing operations was $711.3 million for the 39 weeks ended September 27, 2025, primarily for the purchase of WLFI tokens[231]. - Cash provided by financing activities was $719.4 million for the 39 weeks ended September 27, 2025, mainly from equity financing and notes payable[233]. Future Plans and Segments - The Company plans to separate its Biotechnology segment, which is currently presented as discontinued operations[205]. - The company plans to raise funds to support future development of JAN 123 and may require additional debt financing for new acquisitions and clinical trials[234]. Other Financial Information - The Fintech segment reported revenue of $7.575 million with a gross margin percentage of 34.6% for the 13 weeks ended September 27, 2025[208]. - The Corporate and Other segment generated no revenue for both the 13 weeks ended September 27, 2025, and September 28, 2024[209]. - Unrealized gain on cryptocurrency assets for the 13 weeks ended September 27, 2025, was approximately $72.8 million, marking WLFI tokens to fair value[204]. - The company does not hold any derivative financial instruments[236]. - The company does not hold any securities for trading or speculative purposes[236].

Financial Performance - Preliminary total net product revenue of $369.6 million for Q4 2025 and $1.86 billion for full-year 2025[4] - ELEVIDYS net product revenue reached $110.4 million for Q4 2025 and $898.7 million for full-year 2025[5] - PMO net product revenues totaled $259.2 million for Q4 2025 and $965.6 million for full-year 2025[5] - The company achieved durable revenue of $965.6 million from its PMO franchise, indicating strong performance[3] Cash Position - As of December 31, 2025, the company had approximately $953.8 million in cash, cash equivalents, restricted cash, and investments[6] Sales Guidance - The company reaffirmed a yearly sales floor of $500.0 million for ELEVIDYS, with intentions to exceed it[7] Market Challenges - The fourth quarter revenue for ELEVIDYS was impacted by a severe flu season and rescheduling of patient infusions[3] Future Plans - The company plans to invest fully in approved therapies and advance its next-generation siRNA pipeline in 2026[6] - The company is focused on expanding its portfolio in precision genetic medicine for rare diseases, particularly in Duchenne muscular dystrophy[22] Reporting Timeline - The final and complete financial results for Q4 and full-year 2025 will be reported in late February 2026[7]

Revenue Projections - PTC Therapeutics, Inc. expects to report total unaudited net product and royalty revenue of approximately $823.4 million for the fiscal year ending December 31, 2025[6]. - The company anticipates total unaudited net product revenue of approximately $587.8 million for the same period[6]. - Unaudited net product revenue for Sephience™ (sepiapterin) is expected to be approximately $112.1 million[6]. - For the fiscal year ending December 31, 2026, the company projects total product revenues of $700 million to $800 million, excluding Evrysdi® (risdiplam) royalty revenue and collaboration revenue[7]. Expense Projections - GAAP R&D and SG&A expenses for 2026 are anticipated to be between $775 million and $815 million, while non-GAAP R&D and SG&A expenses are expected to be between $680 million and $720 million[7]. Upcoming Events - The company will provide an update on 2025 accomplishments and highlight 2026 milestones at the 44th Annual J.P. Morgan Healthcare Conference[8]. - The presentation will include preliminary 2025 unaudited financial results and 2026 financial guidance[8]. Financial Reporting - Non-GAAP financial measures are used by management to assess operational trends and provide transparency into the company's performance[10]. - The financial information for 2025 is preliminary and subject to completion of the year-end audit[12]. - The company does not undertake to update or revise forward-looking statements except as required by law[12].

Company Overview - First Watch Restaurant Group, Inc. announced preliminary operational results for Q4 and fiscal year ended December 28, 2025[4]. - The company is listed on the Nasdaq Stock Market under the trading symbol FWRG[2]. - The address of the company's principal executive offices is 8725 Pendery Place, Suite 201, Bradenton, FL 34201[2]. Compliance and Reporting - The report was filed on January 12, 2026, indicating the company's compliance with the Securities Exchange Act of 1934[1]. - The company has not elected to use the extended transition period for complying with new financial accounting standards[3]. - The filing does not incorporate any information by reference into other filings under the Securities Act of 1933[5]. - The report was signed by Mel Hope, Chief Financial Officer and Treasurer[11]. Financial Information - The report does not include specific financial metrics or performance indicators in the provided content[4]. - The company is not classified as an emerging growth company under the Exchange Act[3]. Additional Information - The press release detailing the operational results is attached as Exhibit 99.1[4].

Corporate Update - GRAIL, Inc. plans to present a corporate update and preliminary financial information for the quarter and year ended December 31, 2025 at the 2026 J.P. Morgan Healthcare Conference[4] - The presentation will include results of operations and financial condition, which are expected to be detailed in Exhibit 99.1[6] Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[3]

Financial Results Announcement - KORU Medical Systems, Inc. announced preliminary financial results for the fiscal quarter and year ended December 31, 2025[4]. - The results are based on current estimates and are subject to change pending completion of closing and review procedures[5]. - The press release detailing these results was issued on January 12, 2026[4].

Financial Position - As of December 31, 2025, Vor Biopharma Inc. reported cash, cash equivalents, and short-term investments of approximately $450 million[6] - The financial information provided is preliminary and has not been audited, indicating potential changes upon completion of the audited financial statements[7] Upcoming Events - Vor Biopharma Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, from 10:30 am to 11:10 am PT[9]